Although initially approved by the FDA for adult and pediatric blastic plasmacytoid dendritic cell neoplasm (BPDCN), in December 2018 this agent showed promising cytotoxic activity against CD123-positive AML blast cells in animal models [88]. Here, IL3RA is linked to CD4+/CD56+ hematodermic neoplasm.